Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: HR+ HER2- Breast Cancer

In brief

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Key facts

Study ID

NCT07558733

Run by

Faeth Therapeutics

People needed

32

Starts

2026-04-22

Expected to finish

2033-05-01

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of HR+/HER2- breast cancer.
• Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent.
• Participant has received at least one prior systemic therapy.
• At least 1 measurable or evaluable target lesion according to RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening.
• Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods.

You may not qualify if…

• Participants with triple-negative breast cancer.
• Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
• Active malignancy (except for breast cancer, definitively treated in-situ carcinomas [e.g., breast, cervix, bladder], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
• Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
• Significant cardiovascular impairment.
• Active, uncontrolled infection.
• Concurrent participation in another therapeutic clinical trial.
• Prior radiation therapy within 21 days prior to start of study treatment.
• Participants who have received a prior PI3K, AKT, mTORC1/2, or dual PI3K/mTOR inhibitor.
• Strong CYP3A4 inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or clinically significant CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study.
• Prolongation of QTc interval to >480 ms.
• Type 1 or Type 2 diabetes mellitus on insulin.

Where it is running

• START Los Angeles — Los Angeles, California, United States (enrolling)
• Rocky Mountain Cancer Centers — Lone Tree, Colorado, United States (enrolling)
• Oncology Associates of Oregon — Springfield, Oregon, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• Texas Oncology - Central/South — Austin, Texas, United States (enrolling)
• START San Antonio — San Antonio, Texas, United States (enrolling)
• Texas Oncology - San Aantonio — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.